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Use of Ordinal Outcomes in Vascular Prevention Trials
Comparison With Binary Outcomes in Published Trials
Philip M.W. Bath, MD; Chamila Geeganage, MSc; Laura J. Gray, MSc;
Timothy Collier, MSc; Stuart Pocock, PhD
Background and Purpose—Vascular prevention trials mostly count “yes/no” (binary) outcome events, eg, stroke/no
stroke. Analysis of ordered categorical vascular events (eg, fatal stroke/nonfatal stroke/no stroke) is clinically relevant
and could be more powerful statistically. Although this is not a novel idea in the statistical community, ordinal outcomes
have not been applied to stroke prevention trials in the past.
Methods—Summary data on stroke, myocardial infarction, combined vascular events, and bleeding were obtained by
treatment group from published vascular prevention trials. Data were analyzed using 10 statistical approaches which
allow comparison of 2 ordinal or binary treatment groups. The results for each statistical test for each trial were then
compared using Friedman 2-way analysis of variance with multiple comparison procedures.
Results—Across 85 trials (335 305 subjects) the test results differed substantially so that approaches which used the ordinal
nature of stroke events (fatal/nonfatal/no stroke) were more efficient than those which combined the data to form 2
groups (P0.0001). The most efficient tests were bootstrapping the difference in mean rank, Mann–Whitney U test, and
ordinal logistic regression; 4- and 5-level data were more efficient still. Similar findings were obtained for myocardial
infarction, combined vascular outcomes, and bleeding. The findings were consistent across different types, designs and
sizes of trial, and for the different types of intervention.
Conclusions—When analyzing vascular events from prevention trials, statistical tests which use ordered categorical data
are more efficient and are more likely to yield reliable results than binary tests. This approach gives additional
information on treatment effects by severity of event and will allow trials to be smaller. (Stroke. 2008;39:000-000.)
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Major advances have been made in the primary andsecondary prevention of stroke with effective strategies
based on lifestyle modification, antithrombotic agents, blood
pressure and cholesterol lowering, and carotid endarterecto-
my. In parallel, the absolute risk of recurrence has fallen
dramatically over time; in stroke trials, this is apparent as a
decrease in the control event rate, eg, 10.8% in the Canadian
American Ticlopidine Study (CATS) in 19892 and 3.4% in
Perindopril protection against recurrent stroke study
(PROGRESS) in 2001.3 This trend is likely to continue as
new and effective interventions are added. Because absolute
event rates are a key component in sample size calculations
for binary (“yes/no” event) outcomes, low rates equate to
larger trials.4 An additional pressure in performing trials is
that their number has increased as new prophylactic strategies
are tested, eg, antiplatelets (thromboxane synthase inhibitors),
anticoagulants (thrombin/factor Xa inhibitors), and carotid
interventions (stenting, treatment of asymptomatic stenosis).
The combination of more and larger trials means it is
becoming increasingly difficult to find sufficient patients to
enroll into new studies.
New strategies are required to bring trial sample sizes
down and to maximize the potential to demonstrate benefit. In
the past, composite outcomes of vascular death, nonfatal
stroke, and nonfatal myocardial infarction (MI) have been
used, in part to increase the number of events. This approach
can be extended to include further events in the composite
such as hospitalization, silent brain infarcts (as identified by
MRI), or by counting all vascular events rather than just the
first one.5 However, the use of composite outcomes has been
criticized.6 An alternative approach is to analyze vascular
prevention trials in a way which does not lose clinically
relevant data. Most studies compare binary (stroke/no stroke)
event rates between the treatment and control group. How-
ever, stroke or MI events may be fatal or nonfatal, so
trichotomous outcomes (fatal event/nonfatal event/no event)
can be analyzed. This approach can be extended to 4 (fatal
stroke/severe nonfatal stroke/mild stroke/no stroke) or 5 (fatal
stroke/severe nonfatal stroke/mild stroke/transient ischemic
attack [TIA]/no event) levels. Similar ordered categorical
outcomes can be developed for MI, composite vascular
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outcomes, and bleeding, as well as other vascular events, such
as heart failure. The analysis of such ordered categorical
(ordinal) events is usually more efficient statistically (because
data on severity are not lost) thereby offering the potential for
reducing trial sample size while maximizing the potential to
find small clinically relevant treatment benefits.7 Such poly-
tomization of events assumes that the ordering of events is
meaningful, ie, that fatal vascular events are considered more
severe than nonfatal ones. If so, ordinal outcomes may be
more informative to patients, carers, healthcare professionals,
and government than binary outcomes.
We report a comparison of the relative efficiencies of using
and analyzing binary and polytomous outcomes from vascu-
lar prophylaxis trials. Although the use of ordinal statistical
approaches is well defined in the methodological literature,
its use for designing and analyzing vascular prevention trials
is entirely novel.
Methods
Identification of Trials
We sought summary patient data from randomized controlled trials
assessing primary or secondary vascular prevention, ie, preventing
first or recurrent events respectively, which were either positive or
negative according to the trial publication, or were included in a meta
analysis showing benefit or harm; neutral trials in a neutral meta-
analysis were excluded, an approach which follows our previous
study in acute stroke trials.7 We included vascular trials involving
nonstroke patients and those measuring nonstroke outcomes because
stroke patients suffer subsequent nonstroke vascular events, and
those with other vascular conditions can go on to have a stroke.
Taking this approach means the findings are generalizable across the
field of vascular medicine. Published studies fulfilling these criteria
were identified from electronic searches of the Cochrane Library and
included studies of antithrombotic, BP or lipid lowering therapy,
carotid endarterectomy, and hormone replacement therapy. Trials
were excluded if they were neutral and related to a neutral interven-
tion (as determined from a published meta-analysis) or did not
include adequate ordered categorical information for at least one
vascular outcome.
Trial Data
The numbers of subjects at the end of follow-up having a stroke
(fatal, nonfatal, severe nonfatal, mild, TIA), MI (fatal, nonfatal),
composite vascular event (fatal stroke or MI, nonfatal stroke or MI),
and bleeding (major, minor, no bleeding) were obtained, where
available, for each treatment group (active, control) from the primary
trial publication. In factorial trials or those having more than two
treatment groups,8 data were analyzed for each active comparison
versus control. Data were assessed by intention-to-treat where
possible.
Statistical Tests
We compared different statistical tests for assessing treatment
effect.9–14 Some of these required the ordinal data to be combined
into two groups (eg, Pearson’s Chi-square test), whereas others used
the raw ordered categorical data (eg, Mann–Whitney U test, un-
pooled t test, bootstrapping the mean rank, ordinal logistic regression
[also known as the proportional odds regression]). A description of
the statistical tests used is given in the supplemental Appendix I,
available online at http://stroke.ahajournals.org.
Comparison and Ordering of Statistical Tests
Each data set was analyzed using each statistical test. The results
were then ordered within each trial and given a rank, with the lowest
rank given to the test which produced the smallest probability value
within that trial. A 2-way analysis of variance test (Friedman with
adjustment for ties15; ANOVA) was then performed to assess which
statistical test produced the lowest ranks (ie, the most statistically
significant values). Duncan multiple range test was used to assess the
ordering of tests and determine where significant differences be-
tween tests were present. We also assessed how many statistically
significant (at 5%) results each test found.
To assess the validity and reliability of the results found, a number
of supplementary analyses were carried out. First, the comparison of
statistical tests was repeated within subgroups of trials sharing
similar characteristics to assess whether particular types of trials
suited different statistical approaches; second, the statistical assump-
tions of the tests were assessed; and third, the sensitivity (type 1
error) of the tests was assessed. Technical details of these supple-
mentary analyses can be found in the supplemental Appendix II.
Analyses were carried out in SAS (version 8.2) and Stata (version
7); significance was taken at P0.05 for analyses of trials and
P0.01 for ANOVA.
Results
Trials
Of 243 identified trials, 101 (416 020 subjects) were in-
cluded, these comprising 35 primary and 66 secondary
prevention studies (supplemental Table I). One hundred
forty-two trials were excluded, mostly because their pub-
lished data did not distinguish between fatal and nonfatal
vascular events so that 3-level data could not be calculated
(supplemental Table II).
Stroke
The trials variably included intracerebral hemorrhage within
the outcome of stroke. The results of the statistical tests
differed significantly with 3-level data (fatal stroke/nonfatal
stroke/no stroke; 85 trials, 335 305 subjects; ANOVA
P0.0001); ordinal analyses ranked above binary approaches
(Tables 1 and 2; Figure 1) with the Mann–Whitney U test,
bootstrapping (difference in mean rank), and ordinal logistic
regression significantly better than the other methods (sup-
Table 1. Assessment of 10 Statistical Approaches for
Analyzing Stroke as a 3-Level Event (Fatal/Nonfatal/No Stroke)
in 85 Vascular Prevention Trials
Analysis by 2-way ANOVA (P0.0001) on the ranked data (1 to 10 with 1
“best”); comparison of tests by Duncan’s multiple range test—those tests
joined by the same band are not significantly different from each other at
P0.01.
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plemental Figure I). Similar results were seen for the other
stroke outcome assessments: 4-level (fatal stroke/severe non-
fatal stroke/mild stroke/no stroke), 4-level including TIA
(fatal stroke/nonfatal stroke/TIA/no stroke or TIA), and
5-level (fatal stroke/severe nonfatal stroke/mild stroke/
TIA/no stroke or TIA; each ANOVA P0.0001; Table 2).
Although the absolute ordering of the tests varied for these
polytomous outcomes, ordinal tests always performed better
than binary ones (Table 2). Six trials gave sufficient data to
compare qualitatively 3-, 4-, and 5-level stroke data; 4-level
data (with TIA included as an event) and 5-level data
(including TIA) appeared to be the most efficient approaches.
When assessed by how many trials were statistically signif-
icant (positive or negative but not neutral), those tests which
did not collapse the data into groups again out-performed
other approaches; for example the Mann–Whitney U test
gave a statistically significant result in 44% of trials in
comparison with the Pearson’s 2 2x3 test at 32% (Figure 1).
Myocardial Infarction
Fifty-eight trials (232 515 subjects) were included. The anal-
yses differed significantly for a 3-level outcome (fatal MI/
nonfatal MI/no MI; P0.0001), with ordinal approaches
performing better than binary (Table 2).
Composite Vascular Event
Forty-three trials (204 108 subjects) gave data for a 3-level
composite vascular outcome (fatal stroke or MI/nonfatal
stroke or MI/no stroke or MI). Ordinal tests performed best
(P0.0001) with the Mann–Whitney U test, bootstrapping
(the difference in mean rank) and ordinal logistic regression
ranking highest (Table 2).
Table 2. Ranking of Statistical Tests (1 to 10 With 1 “Best”) for Measure of Stroke (3, 4, and 5-Levels), Myocardial Infarction
(3-Level), Composite Vascular Outcome (3-Level), and Bleeding (3-Level)
Outcome Trials P Value
Ranking of Tests Relative to Each Other
MWU BS OLR RRT CAT t Test 2 23 2 Event 2 Dead Median Test
Fatal stroke/nonfatal
stroke/no stroke
85 0.0001 1 2 3 4 5 6 7 8 9 10
Fatal stroke/severe
nonfatal/mild/no stroke
21 0.0001 2 1 4 3 5 6 8 7 9 10
Fatal stroke/nonfatal
stroke/TIA/no stroke
29 0.0001 2 1 5 6 3 4 7 8 9 10
Fatal stroke/severe
nonfatal stroke/mild
stroke/TIA/no stroke
11 0.0001 3 4 5 6 1 2 8 7 9 10
Fatal MI/nonfatal MI/
no MI
58 0.0001 1 3 5 6 2 4 7 8 9 10
Fatal vascular event/
nonfatal vascular event/
no vascular event
43 0.0001 1 2 3 4 5 6 7 8 9 10
Severe-major bleeding/
minor bleeding/
no bleeding
15 0.0001 3 2 1 6 4 5 8 7 9 10
The most efficient tests are underlined and do not differ from each other statistically.
BS indicates bootstrap; CAT, Cochran–Armitage test; MWU, Mann–Whitney U test; OLR, ordinal logistic regression; RRT, robust ranks test.
Figure 1. The number of significant trials (positive
or negative but not neutral, P0.05) for each sta-
tistical test for 3-level stroke (fatal, nonfatal, no
stroke).
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Bleeding
Fifteen trials (26 215 patients) were identified as including
information on bleeding at three levels: major bleeding,
minor bleeding, no bleeding. Definitions of bleeding differed
between trials. Once again, ordinal analytic approaches
ranked highest (Table 2).
Sensitivity Analysis and Test Assumptions
The ordering of statistical tests, with ordinal more efficient
than binary, was maintained for all subgroups of trials
irrespective of type of prevention and treatment, average age
of patients, trial size and length of follow-up, risk of death or
stroke, and time from index event (Table 3). When consid-
ering the 19 trials (27 datasets) with a high event rate (10%
overall), ordinal tests remained most efficient. Published
hazard ratios (which take into account the time to event, as
derived from the Cox proportional hazards model) for stroke
were available for 36 trials; a comparison of the 11 statistical
tests, including Cox results, revealed bootstrapping, Mann–
Whitney U, and ordinal logistic regression to be as good if not
slightly superior to the Cox model (Duncan multiple range
test).
The statistical assumptions for ordinal logistic regression
were not violated (P0.05) in 79 of 85 trials with 3-level
stroke data; no violations were present for 11 trials with
5-level stroke data (supplemental Appendix III). The sensi-
tivity analysis showed that the top performing statistical tests
(ordinal logistic regression, Mann–Whitney U test) were not
Table 3. Ranking of Statistical Tests (1 to 10 With 1 ‘Best’) for 3-Level Stroke (Fatal, Nonfatal, No Stroke) in Subgroups of Vascular
Prevention Trials
Outcome Trials P Value
Ranking of Tests Relative to Each Other
MWU BS OLR RRT CAT t Test 2 23 2 Event 2 Dead Median Test
Prevention, primary 29 0.0001 1 2 5 3 6 4 7 8 9 10
Prevention, secondary 56 0.0001 2 1 3 4 5 6 7 8 9 10
Anticoagulants 12 0.0001 2 1 7 6 4 3 5 8 9 10
Antiplatelets 33 0.0001 1 2 3 5 4 6 7 8 9 10
Antihypertensives 23 0.0001 2 1 3 4 5 6 7 8 9 10
Lipid lowering 10 0.0001 2 1 3 4 5 6 8 7 9 10
Carotid
endarterectomy
4 0.0001 2 1 5 3 6 4 8 7 9 10
Hormone replacement
therapy
2 0.86                              
Age 65 years 34 0.0001 1 2 3 4 5 6 7 8 9 10
Age 65 years 31 0.0001 2 1 4 3 6 5 7 8 9 10
Trial, small (n2,520) 42 0.0001 1 2 5 6 3 4 7 8 9 10
Trials, large (n2,520) 42 0.0001 2 1 3 4 5 6 8 7 9 10
Follow-up, short term
(36 months)
45 0.0001 1 2 4 5 3 6 7 8 9 10
Follow-up, long term
(36 months)
39 0.0001 2 1 3 4 5 6 7 8 9 10
Risk of death in
control, low
(0.2% per month)
43 0.0001 1 2 3 4 5 6 7 8 9 10
Risk of death in
control, high
(0.2% per month)
41 0.0001 2 1 3 4 5 6 7 8 9 10
Risk of stroke in
control, low
(0.17% per month)
40 0.0001 1 2 3 4 5 6 7 8 9 10
Risk of stroke in
control, high
(0.17% per month)
41 0.0001 2 1 5 6 3 4 7 8 9 10
Time from index
event, short
(87 days)
22 0.0001 1 2 3 4 5 6 8 7 9 10
Time from index
event, long
(87 days)
22 0.0001 2 1 3 6 4 5 7 8 9 10
The most efficient tests are underlined and do not differ from each other statistically.
BS indicates bootstrap; CAT, Cochran–Armitage test; MWU, Mann–Whitney U test; OLR, ordinal logistic regression; RRT, robust ranks test.
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overly sensitive, and statistically significant treatment effects
were only found where they are likely to be present (supple-
mental Appendix III). Using ordinal logistic regression, the
odds ratios were similar for different strata of severity for
3-level, 4-level, and 5-level data (supplemental Table III).
Discussion
Improvements in secondary prevention are leading to falling
event rates in clinical trials. This means that future vascular
prevention trials will need to be longer and, with an increas-
ing number of new interventions, the availability of subjects
is becoming limited. Thus, new approaches to trial design and
analysis are needed to help reduce sample size. This study has
shown that it is feasible to create 3-level ordered categorical
outcomes for stroke, MI, a composite vascular event (fatal
stroke and MI/nonfatal stroke and MI), and bleeding. Anal-
ysis reveals that, in general, statistical approaches which use
ordinal data are more efficient than conventional binary tests
based on “event/no event.” A further increase in efficiency
comes from using 4-level or 5-level data for stroke (with or
without TIA). Ordering vascular events by severity has both
biological and clinical meaning. Fatal events are clearly the
most extreme health state whereas a severe stroke (normally
defined as a stroke resulting in dependency on others) is a
disaster for the patient, their career, and society, for both
clinical and economic reasons. A mild stroke leaves the
patient independent, even if residual impairment remains, and
those who are younger can often return to work.
The most efficient statistical tests were those which exam-
ined ordinal data, including ordinal logistic regression, the
Mann–Whitney U test, and bootstrapping the mean rank. In
addition to improving statistical efficiency, the use of ordered
categorical outcomes gives information on the ability of an
intervention to reduce the severity of an event, not just the
number of events. Ordinal logistic regression allows both
estimation (with confidence intervals) and inclusion of base-
line prognostic covariates in analyses. However, it assumes
that any treatment effect is similar across outcome levels, ie,
the odds of moving a treated patient from fatal to severe
nonfatal stroke are similar to those for moving from TIA to no
event (“proportionality of odds”). This assumption requires
justification because it is neither widely recognized nor
obvious in most published vascular trial data. First, it is
biologically plausible to suggest that prophylactic interven-
tions will reduce severity as well as the total number of
events. Since the development of atherosclerosis and in-
creases in thrombosis, coagulation and inflammation are not
binary events in nature, and their magnitude is a determinant
of the severity of clinical vascular events, it is reasonable to
expect that interventions will move patients from fatal to
severe, severe to mild, and mild to no events. If this
assumption (of proportional odds) is not met, an alternative
ordinal model could be considered.16
Second, there is existing published evidence that interven-
tions do alter severity: simvastatin reduced the risk of stroke
of different severities by similar risk reductions in the Heart
Protection Study (HPS),17 hormone replacement therapy in-
creased both stroke and its severity in the Women’s Estrogen
for Stroke Trial (WEST),18 and antiplatelet agents reduced
both fatal and nonfatal vascular events in the Antithrombotic
Trialists’ (ATT) Collaboration meta analysis.19 The apparent
failure of most vascular prevention trials to show individual
effects on death or severe events is largely because they were
not powered to assess these specific and, therefore, relatively
uncommon events. Third, the odds reduction at each outcome
level appeared to be relatively constant when individual trials
were assessed (Figure 2); formal statistical assessment using
the likelihood ratio test indicated that “proportionality of
odds” was present in most cases (although this test is known
to be conservative; Appendix 6). Last, using ordinal statistical
tests was more powerful than binary approaches, the central
finding of this study. Although this is not a novel idea in the
statistical community,20 ordinal outcomes have not been
applied to vascular prevention trials in the past. In this
context, it is worth noting that ordinal logistic regression is
relatively robust to deviations in its assumptions even if they
are not met in a particular trial. Another efficient ordinal test
is the Mann–Whitney U test, which is widely available in
statistical packages and can produce a point estimate (median
difference between groups) with confidence intervals. The
major assumption of the test is that the treatment groups
should be independent, and this is met here. The final
efficient statistical approach was bootstrapping the mean
rank; this approach is computer intensive13 and its application
and the interpretation of results are not well appreciated by
clinicians, although it is free of assumptions.
The conventional approach to analyzing vascular preven-
tion trials is to perform time to event analyses, as visualized
using Kaplan–Meier curves and analyzed with Cox regres-
sion. When the frequency of events is high, analyses based
on time-to-event are more efficient than those using
frequencies (as analyzed using logistic regression). How-
ever, the frequency of vascular events in most primary and
secondary prevention trials running over 3 to 5 years is
relatively low; recent vascular prevention trials have
tended to report annualized stroke rates of 2% to 4%.21,22
Logistic and Cox models give similar results when the
overall event frequency is less than 10%.23,24 Where the
frequency of events is higher, ordinal data may be analyzed
by time to event.25,26 In the current dataset, the Cox model
was slightly less efficient than bootstrapping, Mann–Whitney
U, and ordinal logistic regression.
In this study, we have focused on assessing stroke as the
primary outcome rather than using a composite vascular
outcome (fatal vascular event, nonfatal stroke, and MI).
Stroke was of interest since it has been used in several
prevention trials, eg, the European Stroke Prevention Study-II
(ESPS-II) and PROGRESS,3,27 and 4- or 5-level data (includ-
ing TIA) may be created. Nevertheless, ordered categorical
outcomes may also be created for composite outcomes (fatal
stroke or MI/nonfatal stroke or MI/no event) as well as other
events such as MI or bleeding. Our results suggest that the use
and analysis of polytomous outcomes would benefit trials
assessing any of these vascular outcomes, and it is likely that
the approach would work for others such as heart failure and
venous thromboembolism; we are currently assessing this.
Using ordered categorical data will mean that results will
need to be reported differently. The results of binary tests are
Bath et al Ordinal Outcomes in Vascular Prevention Trials 5
 at University of Nottingham (not) / England on September 18, 2008 stroke.ahajournals.orgDownloaded from 
summarized easily as the proportion of patients who benefit
(or suffer) with a treatment, ie, oral anticoagulation reduced
absolute stroke recurrence by 1.46% (odds ratio 0.75,
P0.036) in the Anticoagulants in the Secondary Prevention
of Events in Coronary Thrombosis (ASPECT) trial.28 In
contrast, ordinal tests will need to be presented as the average
absolute improvement in outcome, eg, anticoagulation re-
duced stroke recurrence and its severity with an odds ratio of
0.60 (or reduced the mean severity by 0.5 points, P0.013)
on a 5-level scale.28 In this respect, health consumers will
need to decide what odds ratio or difference in events is
worthwhile, both clinically and in terms of health economics.
In reality, it is reasonable to present the primary result using
the odds ratio (or median change in event severity) and to
give the absolute percentage change calculated from the
binary outcome as a secondary measure. Further, a visual
presentation of the data can be displayed as the percentage of
patients within each category by treatment group (data from
the North American Symptomatic Carotid Endarterectomy
Trial [NASCET], Figure 3).
Just as sample size calculations exist for trials using
dichotomised analyses,4 analogous approaches exist for ordi-
nal tests.29 Because ordinal analyses are more powerful
statistically, trial size may be reduced for a given power of
say 90%; eg, sample size falls by 15% to 24% as the number
of outcome categories increases from 3 to 7.29 This reduction
is worthwhile and would reduce competition between trials
for patients, and lower trial costs and complexity. Taking the
Figure 2. Odds ratios across trial (by ordinal logistic regression) and by individual outcome levels for 4 trials to illustrate the
assumption of proportionality of odds.
Figure 3. Example 4-level ordinal data from
NASCET1 of carotid endarterectomy (CEA).
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Hypertension in Elderly Patients (HEP) trial30 as an example
(and assuming significance0.05 and power0.9), the sam-
ple size is reduced by 48% from 1556 for a binary outcome
of stroke/no stroke to 810 for a 3-level stroke outcome as
calculated using the method of Whitehead;29 this is further
reduced to 772 with a 5 level stroke outcome.
A number of caveats must be made about this study. First,
a majority of identified trials could not be included because
they did not publish adequate information on vascular events.
As data were missing for a variety of trial types (primary,
secondary prevention), sizes, and outcome measures (stroke/
MI/vascular/bleeding) it is unlikely that a systematic bias was
introduced into the findings; however, the precision of the
results will have been attenuated by the missing data. Future
trial publications should give this information, including vital
status for the main vascular outcomes, so that ordered
outcome categories can be calculated. Second, we did not use
all possible statistical tests relevant to the problem of analyz-
ing ordered categorical data; instead, we focused on those
approaches which are readily available in statistical text-
books11 and computer packages.
In summary, we suggest that vascular prevention trials
should consider using statistical approaches, which use the
inherent ordered categorical data present within vascular
outcome events. The resulting trials could be smaller (with
savings in patient numbers, numbers of centers, and study
cost and complexity) and would allow appreciation of the
effect of interventions on severity, as well as absolute number
of events, to be highlighted. Appropriate tests include ordinal
logistic regression, the Mann–Whitney U test, and bootstrap-
ping the mean rank.
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Supplemental Appendix I:
Statistical Tests Compared
Included Tests
Univariate statistical approaches for analyzing dichotomous and
ordinal data comprised tests based on Pearson’s Chi-square,
ordinal, and bootstrap approaches.1,2 Ten statistical approaches
were assessed:
(1) Pearson’s Chi-square 22 test—stroke versus no stroke; (2)
Pearson Chi-square 22 test—death versus alive; (3) Pearson’s
Chi-square 23 test (unordered data)—fatal stroke versus non fatal
stroke versus no stroke; (4) Cochran-Armitage trend test; (5) ordinal
logistic regression; (6) median test; (7) Wilcoxon/Mann–Whitney U
test (adjusted for ties); (8) robust ranks test (RRT)3; (9) t test; (10)
bootstrap of difference in mean rank (with 33000 cycles).4,5
Pearson Chi-square tests were performed without continuity correc-
tion because most trials enrolled more than 100 patients.
Statistical Detail for Nonstandard Tests
Robust Rank Test
The Robust rank test3 is an alternative to the Wilcoxon test; it tests
whether the median of one group is equal to another, but unlike the
Wilcoxon test it does not assume that the distributions of the two
groups are equal, ie, it makes no assumptions about the variance of
the two groups.
Bootstrapping
Bootstrapping is a computationally intensive method which involves
resampling data from a given sample. The main advantage of
bootstrapping over more traditional methods is that it does not make
assumptions about the distribution of the data. In this report we
bootstrap the difference in mean rank; the procedure for doing this is
outlined below:
1. Take a dataset, which contains n observations.
2. Draw a sample with replacement of size n (using replacement
means that some of the original observations may appear in the
new sample more than once and some not at all).
3. Estimate the parameter of interest (here the difference in mean
rank) and store the result.
4. Repeat 2 and 3 many times; here we use 3 sets of 3,000 as used
in the ECASS II trial.5
5. Compare the distribution of the stored results to the actual
point estimate from the original dataset.
Ordinal Logistic Regression
Ordinal logistic regression (also called proportional odds regres-
sion)6 can be used when the dependent variable is ordered categor-
ical. It is similar to logistic regression but it simultaneously estimates
multiple end points instead of just one. The number of end points it
estimates is equivalent to the number of ordered categories minus
one. For example if the mRS was the dependent variable of interest
it would compare the following j categories:
0 versus 1, 2, 3, 4, 5, 6
0, 1 versus 2, 3, 4, 5, 6
0, 1, 2 versus 3, 4, 5, 6
0, 1, 2, 3 versus 4, 5, 6
0, 1, 2, 3, 4 versus 5, 6
0, 1, 2, 3, 4, 5 versus 6
Ordinal logistic regression provides one overall estimate for each
covariate in the model and not one for each cut point. This assumes
that the overall odds ratio is constant no matter which cut is taken.
So, for example the odds ratio for the treatment effect would be
interpreted as the odds of being in category j or above for all choices
of j comparing treatment 1 to treatment 0.
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Supplemental Appendix II:
Supplementary Analyses
Subgroup Analysis
Subgroup analyses were performed by assessing the efficiency of the
different tests for differing trial characteristics: type of prevention
(primary, secondary); type of treatment (anticoagulants, antiplatelets,
antihypertensives, lipid lowering, carotid endarterectomy, hormone
replacement therapy); patient age (65, 65 years); trial size
(2520, 2250 participants); length of follow up (36 months,
36 months); baseline severity (control group death rate adjusted for
length of follow up, median [0.2], median [0.2]); time from
index event (87 days, 87 days).
Statistical Assumptions
The principal statistical assumptions underlying the tests which
performed well were assessed to ensure that their use was appropri-
ate for stroke trial data. Assumptions included: ordinal logistic
regression—proportionality of odds across response categories (ie,
the magnitude of improvement or hazard, with a treatment, would be
similar irrespective of baseline severity, age etc); Mann–Whitney
U—independence of groups.
Type 1 Error
While assessing the statistical power of a particular test it is also
important to ensure that the test maintains an acceptable proportion
of type 1 errors (false-positive). A type I error occurs when a
statistical test produces a significant result when in truth no treatment
difference exists. If a test is maintaining adherence to the nominal
proportion of type I errors then, under repeated sampling from a
population in which the null-hypothesis of no treatment effect is true,
we would expect to see a significant result (P0.05) on 5% of
occasions at the 5% significance level.
We assessed the proportion of type I errors for the three most
efficient statistical tests, using data from five representative trials.
From these we generated 1000 data sets, using random sampling
with replacement, in which any treatment difference could have
occurred only by chance. Tests maintaining an acceptable proportion
of type I errors would expect to see a significant result in around 50
of the 1000 data sets.
Supplemental Appendix III: Results
Type 1 Error
Analysis of 1000 resampled random datasets from 5 representative
trials did not find any evidence of an increased proportion of type I
errors for ordinal logistic regression (SPAF-2, positive data sets
n54/1000, P0.301; ESPS-2, n56, P0.212; HOPE, n56,
P0.213; HPS, n46, P0.744; NASCET, n47, P0.69)5;
Mann–Whitney U test (SPAF-2, n21, P0.99; ESPS-2, n30,
P0.99; HOPE, n17, P0.99; HPS, n26, P0.99; NASCET,
n18, P0.99).
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Test Assumptions
When assessing ordinal logistic regression, the assumption of pro-
portionality of odds (likelihood ratio test comparing the multinomial
logistic model to the ordinal logistic regression model) was not met
(P0.05) in 6 of the 85 data sets (ASPECT P0.04,6 TPT-I
P0.0002,7 TPT-II P0.03, HOPE P0.02,3 ANBP2 P0.04,8
WEST P0.059). The same analysis was repeated on the 5-way
stroke data, and the assumption of proportionality of odds was met
for all 11 trials included in this part. In contrast, the assumption of
the Mann–Whitney U test was met in all cases while the bootstrap
approach is assumption free.
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Table I. Appendix 3: Included Trials
Intervention Trial Year Subjects-Prevention Stage Active Group Control Group
Subjects
(Active/Control)
Age
(Years)
Anticoagulation AFASAK1 1989 Chronic nonrheumatic AF:1 Warfarin Placebo 335/336 74
BAATAF2 1990 Non rheumatic AF:1 Warfarin Control 212/208 68
SPAF 13 1991 Non rheumatic AF:1 Warfarin Placebo 210/211 67
VASPNAFI4 1992 Non rheumatic AF:1 Warfarin Placebo 260/265 67
VASPNAFI4 1992 Previous ischaemic stroke:2 Warfarin Placebo 21/25 67
ASPECT5 1994 Post MI:2 Anticoagulant Placebo 1700/1704 61
SPAF 26 1994 Non rheumatic AF:1 Warfarin Aspirin 555/545   
SPAF37 1998 Nonvalvular AF:1 WAsp Adjusted dose W 521/523 72
TPT8 1998 At risk of IHD:1 WAsp Placebo 1277/1272 57
TPT8 1998 At risk of IHD:1 Warfarin Placebo 1268/1272 57
NASPEAF-IM risk9 2004 Patients with MS without prior embolism:1 Combined
(Atriflusal)
Anticoagulant 222/232   
NASPEAF-H risk9 2004 Non valvular AF with prior embolism:2 Combined
(Atriflusal)
Anticoagulant 223/247   
Antiplatelets Acheson10 1969 Post stroke:2 Dipiridamole Placebo 69/70 58
Canadian Co-op11 1978 Recent cerebral or retinal ischaemic
attack:2
Sulphinpyrazone Placebo 156/139   
Breddin12 1980 Post MI:2 Aspirin Placebo 317/309   
Breddin12 1980 Post MI:2 Aspirin Phenprocoumon 317/320   
Herskovits13 1981 Post TIA:2 Pentoxifylline Antiaggregant 30/36 61
ARIS14 1982 Post MI Sulphinpyrazone Placebo 365/362   
AICLA15 1983 Atherothrombotic cerebral or retinal
ischaemic event
Aspirin Placebo 198/204 63
ACCSG16 1985 Recent carotid territory TIAs:2 DipAsp Aspirin 448/442 63
Matius-Guiu17 1987 Post stroke:2 AspDip Dipiridamole 115/71 56
Swedish Co-op18 1987 Post minor or major stroke Aspirin Placebo 253/252 68
TASS19 1989 Post TIA/stroke:2 Ticlopidine Aspirin 1529/1540 63
STIMS20 1990 PAD Ticlopidine Placebo 346/341 60
UKTIA high dose21 1991 Post stroke-TIA:2 Asp high dose Placebo 815/814   
UKTIA low dose21 1991 Post stroke-TIA:2 Asp low dose Placebo 806/814   
SALT22 1991 Post stroke, TIA Aspirin Placebo 676/684 67
SPAF 13 1991 Non rheumatic AF:1 Aspirin Placebo 552/568 67
Fornaro23 1993 Chronic non valvular AF:1 Indobufen Placebo 98/98 62
CAPRIE24 1996 Atherosclerotic vascular disease:2 Clopidogrel Aspirin 9599/9586 62
ESPS 225 1997 Post stroke-TIA:2 Aspirin Placebo 1649/1649 67
TISS26 1997 Post TIA, minor stroke, amaurosis fugax Ticlopidine Indobufen 821/811 65
TPT8 1998 At risk of IHD:1 Aspirin Placebo 1268/1272 57
Taylor27 1999 Carotid stenosis:2 LD Aspirin HD Aspirin 1395/1409 69
TACIP28 2001 Post TIA or non disabling stroke:2 Triflusal Aspirin 1058/1055 65
AAASPS29 2003 Post stroke:2 Ticlopidine Aspirin 902/907 61
Ridker (WHS)30 2005 Healthy women 45 years or older:1 Aspirin Placebo 19 934/19 942 55
BP control VACS197031 1970 Hypertension Active treatment Placebo 186/194 49
Mild HT Oslo32 1980 Mild hypertension:1 Active treatment Control 406/379 45
IPPSH33 1985 Essential Hypertension:1 BB Non BB 3185/3172 52
MRC mild34 1985 Mild hypertension Active treatment Placebo 8700/8654   
(Continued )
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Table I. Continued
Male
(%)
Time From
Event (Weeks)
Follow-Up
(Months)
Control Stroke
Rate (%)
Control MI
Rate (%) Primary Outcome
ICH as
Part
Trial
Result
54    24 4.8    Thromboembolic complications    
72    26 6.25    Ischaemic stroke    
71    15 8.1 0.9 Ischaemic strokesystemic embolism    
      21 7.2    Ischaemic stroke    
      20 16.0    Ischaemic stroke    0
80    37 3.3 9.6 Death from any cause  
      28 6.8 3.5 Ischaemic strokesystemic embolism  0
61    13 2.7 0.9 Ischaemic strokesystemic embolism      
100       2.0 8.4 Coronary deathfatal and non fatal MI  
100       2.0 8.4 Coronary deathfatal and non fatal MI  
      32 2.6    Vascular deathTIAnonfatal stroke or systemic embolism    
      36 4.8    Vascular deathTIAnonfatal stroke or systemic embolism    
69 52 25 5.7 Stroke 0
   1 26 14.4    TIAstrokedeath    0
79    24    8.1 Total mortalitycoronary deathnon fatal MI    0
79    24    5.0 Coronary deathnon fatal MI    0
76    12 2.8    TIAstroke    
      19 1.6 9.4 Fatalnon fatal MIother thromboembolic episodessudden
deathother cardiac death
   
70    36 16.1 4.4 Fatalnon fatal cerebral infarction  0
67 3 25 19.0    Strokeretinal infarctiondeath 0
77 1 40 12.7    Stroke    0
62    24 12.7 3.6 Recurrent stroke or death  0
65    28 13.8    Stroke    
76    60 6.5 19.9 StrokeTIAMI  0
73    48 14.6    Strokemyocardial infarctionvascular death    
73    48 14.6    Strokemyocardial infarctionvascular death    
66 8 32 16.2 9.9 Strokeall death 
71    15 7.4 2.1 Ischaemic strokesystemic embolism 
51    36 5.1    Ischaemic strokeTIAsystemic embolismpulmonary
embolismfatal MI
   
72    23 1.9 3.9 Ischaemic strokemyocardial infarction or vascular death  
58    24 15.1 2.7 Stroke    
63    12 3.6 0.6 Non fatal strokenon fatal MIvascular death from any other
cause
   
100       2.0 8.4 Coronary deathfatal and non fatal MI  
70    3 6.0 2.5 StrokeMIdeath  
66 30 10.6    Vascular deathnon fatal ischaemic strokenon fatal MI  0
      24 9.48 0.9 Recurrent strokeMI or vascular death    0
0    121 1.3 0.9 Non fatal MInon fatal strokedeath from cardiovascular
caues
   0
100    36    2.6 Death    
100    66    2.1       0
50    60 1.5 2.3 Sudden cardiac deathfatal MINon fatal MICVA    0
      60 1.3 2.7 Stroke    
(Continued )
Bath et al Ordinal Outcomes in Vascular Prevention Trials 11
 at University of Nottingham (not) / England on September 18, 2008 stroke.ahajournals.orgDownloaded from 
Table I. Continued
Intervention Trial Year Subjects-Prevention Stage Active Group Control Group
Subjects
(Active/Control)
Age
(Years)
HEP35 1986 Hypertension (old) Atenalol/
Bendrofluazide
Control 348/377 69
SHEP36 1991 hypertension:2 (systolic) Active treatment Placebo 2365/2371 72
MRC old37 1992 Hypertension (old) Diuretic Placebo 1081/2213 70
MRC old37 1992 Hypertension (old) Beta blocker Placebo 1102/2213 70
PATS38 1995 Hypertensionpost stroke/TIA:2 Indapamide Placebo 2841/2824 60
Syst China39 1998 Hypertension (systolic) Active treatment Placebo 1253/1141 67
UKPDS 3840 1998 Diabetes Tight Less tight 758/390 56
ABCD41 1998 Hypertension Nisoldipine Enalapril 235/235 58
UKPDS-3942 1998 Type 2 diabetes Captopril Atenolol 400/358 56
CAPPP43 1999 Hypertension:2 Captopril Conventional
treatment
5492/5493 52
NICH-EH44 1999 Elderly hypertension:1 Nicardipine Trichlormethiazide 204/210 70
Syst-Eur45 1999 Hypertension (systolic) Active treatment Placebo 2398/2297 70
STOP-HT46 1999 Hypertension:2 ACE inhibitors Conventional drugs 2205/2213 76
STOP-HT46 1999 Hypertension:2 Calcium
antagonists
Conventional drugs 2196/2213 76
HOPE47 2000 Having cardiovascular risk factors:2 Ramipril Placebo 4645/4652 66
INSIGHT48 2000 Hypertension Nifedipine Co-amilozide 3157/3164 65
NORDIL49 2000 Hypertension Diltiazem Diureticsbeta
blocker
5410/5471 60
MacMahon50 2000 Post MI, TIA, PVD Ramipril Placebo 308/309 61
PROGRESS51 2001 Hypertension, post stroke/TIA:2 Perindopril
Indapamide
Placebo 3051/3054 64
OPTIMAL52 2002 Post MI:2 Losartan Captopril 2744/2733 67
ANBP253 2003 Hypertension (old) Enalapril Hydrochlorothiazide 3044/3039 80
DIABHYCAR54 2004 Type 2 diabetes Ramipril Placebo 2443/2469 65
SCOPE55 2004 Hypertension (old, systolic) Candesartan Control 754/764 77
Statins 4S56 1994 Patients with coronary heart disease;2 Simvastatin Placebo 2221/2223   
KAPS57 1995 Atherosclerosis:1 Pravastatin Placebo 212/212 57
REGRESS58 1995 Coronary atherosclerosis:2 Pravastatin Placebo 450/434 56
WOSCOPS59 1995 Coronary heart disease:2 Pravastatin Placebo 3302/3293 55
CARE60 1996 Post MI:2 Pravastatin Placebo 2081/2078 59
Post CABG61 1997 Coronary heart disease:2 Aggressive
treatment
Moderate treatment 676/675 62
LIPID62 1998 Coronary heart disease:2 Pravastatin Placebo 4512/4502 62
BIP63 2000 Coronary heart disease:2 Bezafibrate Placebo 1548/1542 60
GISSIP-P64 2000 Coronary heart disease:2 Pravastatin Control 2138/2133   
SCAT65 2000 Coronary heart disease:2 Simvastatin Placebo 230/230 61
MIRACL66 2001 Coronary heart disease:2 Atorvastatin Placebo 1538/1548 65
HPS67 2002 CHD (stroke):2 Simvastatin Placebo 10 269/10 267 64
PROSPER68 2002 Elderly with risk factors for cardiovascular
disease
Pravastatin Placebo 2891/2913 75
ALLHAT-LLT69 2002 Coronary heart disease:2 Pravastatin Control 5170/5185 66
ALERT70 2003 Renal transplant Fluvastatin Placebo 1050/1052 50
CARDS71 2004 Type 2 diabetes:1 Atorvastatin Placebo 1428/1410   
(Continued )
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Table I. Continued
Male
(%)
Time From
Event (Weeks)
Follow-Up
(Months)
Control Stroke
Rate (%)
Control MI
Rate (%) Primary Outcome
ICH as
Part
Trial
Result
31    53 10.3 10.1 MIstrokeTIA    
43    54 6.9 4.2 Non fatal strokefatal stroke    
42    70 6.1 7.2 Strokecoronary eventsdeath from all causes    
42    70 6.1 7.2 Strokecoronary eventsdeath from all causes    0
72    24 7.7    Fatal strokenon fatal stroke    
64    36 5.3 0.6 Fatal strokenon fatal stroke    
55    101 9.5 18.2 Diabetes death or complications    
67    67 3.0 2.1 MI      
54       4.7 12.6 Fatal and non fatal related to diabetesdiabetes deathall
cause mortality
   0
53    73 2.7 2.9 Fatal MInon fatal MIstrokeother cardiovascular deaths    0
33    60 3.8 1.0     0
      24 3.5    Stroke    
33       10.7 6.9 Fatal strokefatal MIother fatal cardiovascular disease    0
33       10.7 6.9 Fatal strokefatal MIother fatal cardiovascular disease    0
73    60 4.8 12.2 MIstrokedeath from cardiovascular causes    
46    51 2.3 1.9 Cardiovascular deathMIheart failurestroke    0
51    54 3.6 2.9 Fatal and non fatal strokeMIother cardiovascular death    0
82    56    10.7 Carotid atherosclerosisleft ventricular mass    0
70    47 14.0    Total stroke (fatal or non fatal)  
71    32 4.8 13.8 All cause mortality    0
49    49 3.6 2.7 All cardiovascular eventsdeath from any cause    
70    48 4.7 3.2 Cardiovascular deathnon fatal acute MIStrokeheart
failureend stage renal failure
   0
36    43 4.6 3.5 Cardiovascular deathnon fatal MInonfatal stroke    
81    65 2.5 19.9 Total mortality  
100    36 1.9 3.8 Rate of carotid atherosclerotic progression    
100    24    2.9 Change in average MSDMOD per patient    
      59    7.8 Non fatal MIdeath from CHD    
86    60    9.9 Fatal coronary eventnon fatal MI    
92    52 2.2 5.9 Rate of progression of atherosclerosis in the graft    
83    73 4.5 10.2 Mortality from coronary heart disease    
91    74 4.9 12.3 Fatal or non fatal MIsudden death    0
86    24 0.9 2.4 Total mortalitynon fatal MIstroke    
89    48 3.0 4.3 DeathMIstrokerevascularisation   
65    16 1.6    Deathnon fatal MI    
75       6.0 12.5 Death  
48    38 4.6 12.9 Death from coronary heart diseasenon fatal MIfatal or non
fatal stroke
   
51    58 4.5 8.1 All cause mortality      
66    61 5.9 11.4 Cardiac deathnon fatal MIcoronary intervention    0
      47 2.5 4.3 Acute coronary heart diseasecoronary
revascularisationstroke
   
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Table I. Continued
Intervention Trial Year Subjects-Prevention Stage Active Group Control Group
Subjects
(Active/Control)
Age
(Years)
SPARCL72 2006 Post TIA/stroke:2 Atorvastatin Placebo 2365/2366 63
Surgery NASCET73 1991 Post stroke:2 CEA Medical 328/331 66
VACS74 1993 Asymptomatic carotid stenosis Surgical
treatment
Medical treatment 211/233 64
ACAS75 1995 Asymptomatic carotid stenosis Immediate
surgery
Deferred surgery 825/834 67
ACST76 2004 Asymptomatic carotid stenosis Immediate
surgery
Deferred surgery 1560/1560 68
HRT ERA77 2000 Coronary heart disease:2 HRT Placebo 204/105 66
WEST78 2001 Post stroke, TIA:2 Estradiol Placebo 337/327 71
Clarke79 2002 Coronary heart disease:2 HRT Control 134/121 67
WHI-EP80 2003 Post menopausal women:1 EstrogenProgestin Placebo 8506/8102 63
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Table I. Continued
Male
(%)
Time From
Event (Weeks)
Follow-Up
(Months)
Control Stroke
Rate (%)
Control MI
Rate (%) Primary Outcome
ICH as
Part
Trial
Result
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66    40 8.4    Stroke  
0    38    7.6 Mean minimal coronary artery diameter    0
0    34 17.1 5.2 Deathnon fatal strokeTIAnon fatal MI    
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Table II. Excluded Trials
Trial Year Patient Group n Reason for Exclusion
BP lowering VACSG1 1967 Male hypertensive patients 143 Relevant outcome data not available
Co-op RCT2 1973 Patients with diastolic BP 100–120 58 Relevant outcome data not available
Sprackling3 1981 Elderly hypertensive patients 123 Relevant outcome data not available
EWPHE4 1985 Elderly hypertensive patients 840 Relevant data not available
Wikstrand5 1986 Elderly hypertensive patients 562 Relevant data not given
BBB6 1988 Hypertension 2127 Neutral
TOMHS7 1993 Patients with hypertension aged 45 to 69 years 902 Neutral
ASIST8 1994 Patients with coronary artery disease 306 Relevant outcome data not available
CIBIS9 1994 Patients with chronic heart failure 641 Relevant outcome data not available
HYCAR10 1995 Patients with hypertension and LVH 115 Relevant outcome data not available
GLANT11 1995 Patients with mild to moderate essential hypertension 1936 Neutral
STONE12 1996 Patients with hypertension 1632 Relevant data not given
MIDAS13 1996 Patients with hypertension 883 Relevant data not given
ACCT14 1996 Patients with essential hypertension 1084 Relevant outcome data not available
ELITE15 1997 Patients aged 65 or more with heart failure 722 Relevant outcome data not available
VHAS16 1997 Patients with hypertension 1414 Relevant outcome data not available
LOA17 1997 Patients with hypertension 898 Relevant outcome data not available
AIREX18 1997 Patients with heart failure after MI 603 Relevant outcome data not available
VHAS19 1998 Patients with hypertension 456 Relevant outcome data not available
FACET20 1999 Patients with hypertension and NIDDM 380 Relevant data not given
HOT21 1998 Patients with hypertension 18 790 Neutral
Tuomilehto22 1999 Older patients with diabetes and systolic hypertension 4695 Relevant outcome data not available
ALLHAT23 2000 Patients with hypertension 55 years or older 33 357 Relevant outcome data not available
PREVENT24 2000 Patients with coronary atherosclerosis 825 Relevant outcome data not available
ATIME25 2000 Patients with hypertension 2935 Relevant outcome data not available
CALM26 2000 Patients with type 2 diabetes having hypertension and
microalbuminurea
197 Relevant data not given
ELITE-227 2001 Patients with symptomatic heart failure 3152 Relevant outcome data not available
CONVINCE28 2001 Patients with hypertension 16 602 Relevant outcome data not available
CAPRICON29 2001 Patients had MI 1959 Relevant data not available
CASTLE30 2001 Patients with mild hypertension 251 Relevant data not available
AASK31 2002 Patients 18–70 years with hypertensive renal disease. 1094 Relevant outcome data not available
LIFE32 2002 Patients with essential HT and LVH ascertained by ECG 9193 Relevant outcome data not available
ELSA33 2002 Patients with hypertension 2334 Relevant outcome data not available
EUROPA34 2003 Patients with previous MI, coronary revascularisation,
angiographic evidence of CAD or positive stress test
18 328 Relevant outcome data not available
CHARM-preserved35 2003 Patients had NYHA class 11-1V CHF and LVEF 40% 3023 Relevant outcome data not available
CHARM-alternative36 2003 Patients with symptomatic heart failure(NYHA class 11-1V),
LVEF 40% or less and intolerance to ACEIs
2028 Relevant outcome data not available
CHARM-added37 2003 Patients had NYHA class 11-1V, LVEF 40% or less and being
treated with ACEIs
2548 Relevant outcome data not available
NICOLE38 2003 Patients who has undergone successful coronary angioplasty 826 Relevant data not given
E-COST39 2003 Patients with essential hypertension 2048 Relevant outcome data not available
SHELL40 2003 Elderly patients with isolated systolic hypertension 1882 Neutral
Berl41 2003 Patients with diabetic nephropathy and hypertension 1715 Relevant outcome data not available
CAMELOT42 2004 Patients with coronary artery disease and normal blood
pressure
1991 Relevant outcome data not available
JMIC-B43 2004 Patients with hypertension and coronary artery disease 1650 Relevant outcome data not available
PEACE44 2004 Patients with stable coronary artery disease having normal or
reduced LV function
8290 Relevant outcome data not available
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Table II. Continued
Trial Year Patient Group n Reason for Exclusion
VALUE45 2006 Patients with hypertension and high cardiovascular risk 15 245 Relevant outcome data not available
ACTION46 2004 Patients with treated stable symptomatic coronary disease 3825 Relevant outcome data not available
ASCOT-BPLA47 2005 Hypertension 19 257 Relevant data not given
ADVANCE48 2005 Hypertension 11 140 Relevant data not given
MOSES49 2005 Hypertensive stroke patients 1405 Relevant data not given
Gradman50 2005 Patients with hypertension 652 Relevant data not given
Hermida51 2005 Patients with essential hypertension 200 Relevant data not given
Stokes52 2005 Patients with systolic hypertension 16 Relevant outcome data not available
Ernst53 2006 Untreated hypertensive patients 30 Relevant data not given
Kushiro54 2006 Patients with hypertension Relevant data not given
HRT Marmorston55 1962 Previous cerebrovascular disease 200 Relevant outcome data not available
VACS56 1966 Males with atherosclerotic myocardial infarction and cerebral
infarction
582 Relevant data not given
McDowell57 1967 Post-menopausal women with non embolic cerebral infarction 176 Relevant data not given
Nachtigall58 1979 Post-menopausal women 2 or more years after menopause 329 Relevant data not given
Hall59 1994 Post menopausal women with rheumatoid arthritis 200 Relevant data not given
PEPI60 1995 Post-menopausal women age 45 to 64 875 Relevant data not given
Hall61 1998 Post-menopausal women with coronary heart disease 60 Relevant data not given
Hulley62 1998 Post menopausal women with established coronary heart
disease
2763 Relevant outcome data not available
Mijatovic63 1998 Post menopausal women 52 Relevant data not given
HERS64 1998 Post-menopausal women with established coronary heart
disease
2763 Relevant outcome data not available
Ravn65 1999 Post menopausal women 45 to 59 years of age 1609 Relevant outcome data not given
Recker66 1999 Women older than 65 years and having low bone mass 128 Relevant outcome data not available
Komulainen67 1999 Non osteoprotic early post menopausal women 464 Relevant outcome data not available
MORE68 1999 Osteoporotic post-menopausal women 7705 Relevant outcome data not available
Mulnard69 2000 Women with mild to moderate AD, MMSE 12–28 and had a
hysterectomy
120 Relevant outcome data not available
EWA70 2000 Post-menopausal women with angiographically verified
coronary heart disease
118 Relevant data not given
EVTET71 2000 Post-menopausal women who suffered previous DVT or PE 140 Relevant data not given
Mosekilde72 2000 Post menopausal women 2016 Relevant outcome data not available
Gallagher73 2001 Post menopausal women with normal bone density 489 Relevant outcome data not available
PHOREA74 2001 Post-menopausal women 264 Relevant outcome data not available
Binder75 2001 Post-menopausal women 75 years of age or older 59 Relevant data not given
EPAT76 2001 Post menopausal women without pre-existing cardiovascular
disease
222 Relevant outcome data not available
WAVE77 2002 Post-menopausal women with coronary stenosis 423 Relevant outcome data not available
ESPRIT78 2002 Post-menopausal women survived first MI 1017 Relevant outcome data not available
Giske79 2002 Apparently healthy peri and post menopausal women 166 Relevant outcome data not given
Arrenbrecht80 2002 Non osteoporotic post menopausal volunteers 160 Relevant outcome data not given
Haines81 2003 Post menopausal Chinese women 152 Relevant outcome data not available
HABITS82 2004 Female patients with previous breast cancer 434 Relevant outcome data not available
Anticoagulants Olsson83 1980 Patients who had TIA or RIND 156 Neutral
CAFA84 1991 Patients with chronic atrial fibrillation 378 Relevant outcome data not available
EAFT85 1995 Patients with non rheumatic AF and recent minor IS 214 Relevant outcome data not available
SPRIT86 1997 Patients after cerebral ischaemia of presumed arterial origin 1316 Relevant outcome data not available
CARS87 1997 Patients who had MI 8803 Neutral
Hellemons88 1999 Atrial fibrillation 729 Neutral
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Table II. Continued
Trial Year Patient Group n Reason for Exclusion
AFASAK 289 1999 Patients with non valvular chronic atrial fibrillation 677 Neutral
HEAST90 2000 Atrial fibrillation 449 Relevant outcome data not available
Yamaguchi91 2000 Atrial fibrillation Relevant outcome data not available
WARSS92 2001 Patients had noncardioembolic IS within previous 30 days 2206 Relevant outcome data not available
ASPECT 293 2002 Patients with ischaemic heart disease 661 Relevant outcome data not available
SPINAF94 2005 Patients with non rheumatic atrial fibrillation 525 Relevant data not given
WASID95 2005 Patients had TIA or stroke 569 Neutral
SPORTIF96 2005 Patients with nonvalvular atrial fibrillation 3922 Neutral
Antiplatelets Elwood97 1974 Male patients who had recent MI 1239 Relevant outcome data not available
AITIA98 1977 Patients who had carotid TIAs 178 Relevant outcome data not available
Vogel99 1979 Patients with previous MI 1340 Relevant outcome data not available
Elwood100 1979 Patients had confirmed MI 1682 Relevant data not given
ART101 1980 Patients with previous MI 1558 Relevant outcome data not available
CDPA102 1980 Patients with previous MI 2915 Relevant outcome data not available
PARIS-1103 1980 Patients with previous MI 2026 Relevant outcome data not available
PARIS-2104 1986 Patients recovered from MI 4wks to 4 month previously 3128 Relevant outcome data not available
Boysen105 1988 Patients after carotid endarterctomy 301 Neutral
Hass106 1989 Patients had previous TIA, amaurosis fugax, RIND or minor
stroke
3069 Relevant outcome data not available
CATS107 1989 Patients with previous thromboembolic stroke 1072 Relevant outcome data not available
Dutch TIA108 1991 Patients had TIA or minor ischaemic stoke 3131 Relevant outcome data not available
PACE pilot109 1994 Elderly patients without a pre-existing clinical history of
cardiovascular disease
400 No outcome data available
EPIC110 1995 Patients with coronary artery disease 2099 Relevant outcome data not available
Kereiakes111 1998
ESPS 1112 1998 Patients with recent stroke, TIA or RIND 1306 Relevant outcome data not available
EXCITE113 2000 Patients with angiographic evidence of clinically significant
coronary artery disease
7232 Neutral
APLAUD114 2000 Patients with recent cardiovascular or cerebrovascular event 451 Relevant outcome data not available
TACIP115 2003 Patients who suffered from TIA or non disabling stroke 2113 Neutral
ESPRIT116 2003 Patients with recent cerebral ischaemia of arterial origin 591 Relevant outcome data not available
TAPIRSS117 2004 Patients with previous cerebrovascular event 431 Neutral
MATCH118 2004 Patients with recent ischaemic stroke or TIA 7599 Neutral
PLUTO-Stroke119 2005 Patients after ischaemic stroke 70 Relevant outcome data not available
CARESS120 2005 Patients with symptomatic carotid stenosis 107 Relevant outcome data not available
CHARISMA121 2006 Patients with clinically evident cardiovascular disease 15 603 Neutral
Statins ACAPS122 1994 Patients with moderately elevated cholesterol levels and free of
symptomatic cardiovascular disease
1953 Relevant outcome data not available
CCAIT123 1994 Patients with diffuse coronary atherosclerosis 331 Relevant data not given
Weintraub124 1994 Patients with coronary artery disease 404 Relevant outcome data not available
Shepherd125 1995 Male patients with hypercholestrolemia 6595 Relevant outcome data not available
CCAIT126 1996 Patients with coronary atherosclerosis 331 Relevant outcome data not available
PLAC 1127 1995 Patients with coronary artery disease 408 Relevant outcome data not available
CIS128 1997 Male patients with coronary artery disease and
hypercholesterolemia
254 Relevant outcome data not available
AFCAPS/TexCAPS129 1998 Patients with average TC and LDL-C and below average HDL-C 6605 Relevant outcome data not available
Riegger130 1999 Patients with symptomatic coronary heart disease and
hyperlipidaemia
365 Relevant outcome data not available
Brown131 2001 Patients with coronary artery disease and low HDL cholesterol
levels
160 Relevant outcome data not available
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Table II. Continued
Trial Year Patient Group n Reason for Exclusion
DIAS132 1996 Patients with type 2 diabetes and atherosclerosis 731 Relevant outcome data not available
LIPIS133 2002 Patients underwent their first PCI 1677 Relevant outcome data not available
ASCOT-LLA134 2003 Patients with hypertension 10 305 Relevant outcome data not available
Surgery Eikelboom135 1988 Patients undergoing CEA 129 Relevant data not available
Clagett136 1989 Patients undergoing CEA 152 Relevant data not available
Lord137 1989 Patients undergoing CEA 140 Relevant outcome data not available
CASANOVA138 1991 Patients with carotid stenosis 410 Neutral
Shah139 1994 Patients undergoing CEA 873 Relevant data not available
Katz140 1994 Patients undergoing CEA 100 Relevant data not available
Myers141 1994 Patients undergoing CEA 136 Relevant data not available
Rockman142 1996 Patients undergoing CEA 3975 Relevant data not available
AbuRahama143 1997 Patients undergoing CEA 399 Relevant outcome data not available
Fiorani144 1997 Patients with carotid stenosis 1020 Relevant data not available
ECST145 1998 Patients with carotid stenosis 3018 Relevant outcome data not available
Stoughton146 1998 Patients with carotid stenosis 208 Relevant outcome data not available
Sbarigia147 1999 Patients with carotid stenosis 107 Relevant outcome data not available
McCarthy148 2002 Patients with carotid stenosis 240 Neutral
CAVATAS149 2001 Patients with carotid stenosis 504 Neutral
Yadav150 2004 Patients undergoing CEA 334 Relevant outcome data not available
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Table III. Odds Ratios for Example Trials for Different Outcome Levels
A. Stroke, 3 Levels: Fatal Stroke/Nonfatal Stroke/No Stroke
Trial
Odds Ratio (95% Confidence Intervals)
Overall Fatal Versus Alive Stroke Versus No Stroke
HPS 0.736 (0.651–0.833) 0.805 (0.614–1.054) 0.736 (0.650–0.832)
ESPS 2 0.740 (0.594–0.921) 0.999 (0.536–1.864) 0.737 (0.591–0.918)
PROGRESS 0.710 (0.608–0.828) 0.839 (0.555–1.268) 0.708 (0.606–0.826)
HOPE 0.678 (0.551–0.835) 0.385 (0.219–0.674) 0.681 (0.553–0.838)
MRC mild 0.545 (0.397–0.747) 0.662 (0.365–1.204) 0.544 (0.397–0.747)
B. Stroke, 4 Levels: Fatal Stroke/Nonfatal Severe Stroke/Mild Stroke/No Stroke
Trial
Odds Ratio (95% Confidence Intervals)
Overall Fatal Versus Alive Severe Versus Mild Mild Versus No Stroke
HPS 0.735 (0.642–0.842) 0.804 (0.614–1.053) 0.808 (0.645–1.013) 0.734 (0.641–0.841)
SPAF 1 0.550 (0.326–0.927) 1.546 (0.257–9.291) 0.737 (0.358–1.519) 0.545 (0.323–0.918)
SALT 0.798 (0.591–1.077) 1.425 (0.629–3.232) 0.814 (0.514–1.289) 0.793 (0.587–1.071)
HEP 0.521 (0.298–0.912) 0.281 (0.092–0.854) 0.409 (0.186–0.896) 0.528 (0.302–0.925)
NASCET 0.473 (0.302–0.789) 0.400 (0.077–2.077) 0.327 (0.157–0.683) 0.482 (0.308–0.755)
C. Stroke, 4 Levels: Fatal/Nonfatal/TIA/No Stroke
Trial
Odds Ratio (95% Confidence Intervals)
Overall Fatal Versus alive Stroke Versus TIA TIA Versus No stroke
SPARCL 0.764 (0.663–0.881) 0.581 (0.350–0.965) 0.824 (0.694–0.980) 0.759 (0.658–0.875)
SPAF 1 0.539 (0.340–0.854) 1.546 (0.257–9.291) 0.545 (0.323–0.918) 0.536 (0.338–0.850)
ESPS 2 0.553 (0.472–0.647) 0.907 (0.493–1.669) 0.588 (0.476–0.728) 0.545 (0.465–0.640)
Ridker 0.804 (0.705–0.918) 1.046 (0.583–1.877) 0.829 (0.693–0.992) 0.804 (0.704–0.917)
HEP 0.529 (0.312–0.895) 0.281 (0.092–0.854) 0.528 (0.302–0.925) 0.536 (0.316–0.907)
D. Stroke 5-level: fatal stroke/severe/mild/TIA/no stroke
Trial
Odds Ratio (95% Confidence Intervals)
Overall Fatal Versus Alive Severe Versus Mild Mild Versus TIA TIA Versus No Stroke
ASPECT 0.598 (0.397–0.899) 1.381 (0.554–3.441) 0.665 (0.365–1.211) 0.625 (0.410–0.954) 0.596 (0.396–0.896)
SPAF 3 2.676 (1.705–4.201) 5.058 (0.589–43.444) 2.790 (1.163–6.694) 3.605 (1.959–6.633) 2.644 (1.684–4.152)
HEP 0.528 (0.312–0.894) 0.281 (0.092–0.854) 0.409 (0.186–0.896) 0.528 (0.302–0.925) 0.536 (0.316–0.907)
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Figure I. Ordering of statistical tests for
stroke (3, 4 and 5-level), myocardial
infarction (3-level), vascular events
(3-level) and bleeding (3-level). Ordinal
tests (Mann–Whitney U test, ordinal
logistic regression) were superior (lower
rank) to dichotomous tests.
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